Abstract: The invention has as object a cementitious composition for forming mortars or concretes having reduced tendency to react with alkali, characterized in that it comprises as additive at least a compound of general formula: [R—N—(CH2—COOH)n]x??(I) R being an aliphatic or aromatic hydrocarbon chain, n=2 or 3 and x=1 or 2.

Abstract: Provided is a method for preparing stable free flowing solid aminocarboxylate chelants by adding to a chelant that contains residual alkaline metal hydroxide a free or partially neutralized carboxylic acid such that the free or partially neutralized acid neutralizes at least a portion of the alkaline metal hydroxide; and isolating therefrom the free-flowing solid chelant.

Abstract: Nitrogen-containing lipids prepared from the conjugate addition of amines to acrylates, acrylamides, or other carbon-carbon double bonds conjugated to electron-withdrawing groups are described. Methods of preparing these lipids from commercially available starting materials are also provided. These amine-containing lipids or salts forms of these lipids are preferably biodegradable and biocompatible and may be used in a variety of drug delivery systems. Given the amino moiety of these lipids, they are particularly suited for the delivery of polynucleotides. Complexes or nanoparticles containing the inventive lipid and polynucleotide have been prepared. The inventive lipids may also be used to in preparing microparticle for drug delivery. They are particularly useful in delivering labile agents given their ability to buffer the pH of their surroundings.

Abstract: A composition includes a first chelating agent, a second chelating agent, and a plurality of metal ions. In one embodiment, the second chelating agent includes citric acid and is different than the first chelating agent. A method for forming a composition includes mixing a first chelating agent, a second chelating agent, and a metal salt together to form a mixture and processing the mixture to form at least one of a granulated composition and a powdered composition. In some embodiments, the second chelating agent includes citric acid and is different than the first chelating agent.

Abstract: One embodiment of the present invention relates to ionic liquids and ionic viscoelastics formed between [1] a small molecule or macromolecule containing two or more cations; and [2] a small molecule or macromolecule containing two or more anions. Another embodiment of the invention is the use of the inventive ionic liquids and ionic viscoelastics, formed between a small molecule or macromolecule containing two or more cations and a small molecule or macromolecule containing two or more anions, to form a crosslinked network. In certain embodiments, the ionic liquids formed can be viscous liquids, viscous liquid formed networks, or viscoelastic networks/gels. In certain embodiments, the ionic material of the invention may be used for a variety of applications including, but not limited to, lubricants, additives, gas separation, liquid separation, membranes, fuel cells, sensors, batteries, coatings, heat storage, liquid crystals, biocompatible fluids, solvents, and electronic materials.

Abstract: The invention relates to the use of ethylenediamine tetraacetic acid (EDTA) and its derivatives, i.e. its salts and complexes for prevention and treatment of bacterial intestinal diseases of pigs and for increasing the effects of antibiotics exerted in such diseases. The invention also relates to compositions for animal husbandry, i.e. to veterinary compositions and to feeds and drinks which can be consumed by pigs, comprising EDTA or its derivatives.

Abstract: The present invention provides a liquid pharmaceutical formulation comprising a therapeutic protein, a surfactant and at least an antioxidant selected from the group of radical scavengers, chelating agents or chain terminators.

Abstract: Compositions including a comb polymer and an Fe(III)-complexing agent X selected from the group consisting of thiocyanates, condensed phosphates, amines, amino acetic acids, oxycarboxylic acids and compounds of the formula (V). The invention also relates to a method for stabilizing comb polymers in the presence of Fe(III) using such Fe(III)-complexing agents X.

Abstract: A process for producing granules containing one or more complexing agent salts of the general formula from an aqueous starting solution, containing the one or more complexing agent salts in a concentration of from 10 to 80% by weight, based on the total weight of the aqueous starting solution, in a jet apparatus.

Abstract: The invention comprises a hard surface cleaning composition including an environmentally friendly, surfactant derived from renewable bio-based resources. The cleaning composition includes a mixture of alkyl polypentosides and alkyl polyglucosides having primarily between 8 and 11 carbon atoms as a surfactant, an acid source, an optional solvent, a water conditioning agent and water. The hard surface cleaner is preferably substantially free of alkyl phenol ethoxylates and is effective at removing food soils including 20% protein.

Abstract: Provided is a method for preparing stable free flowing solid aminocarboxylate chelants by adding to a chelant that contains residual alkaline metal hydroxide a free or partially neutralized carboxylic acid such that the free or partially neutralized acid neutralizes at least a portion of the alkaline metal hydroxide; and isolating therefrom the free-flowing solid chelant.

Abstract: Methods and compositions are provided for the reduction of fouling of objects present in marine environments. The methods and compositions include anticoagulants, such as, for example, glycosaminoglycans, coumarin-type molecules, metal chelators, plasminogen activators and platelet inhibitors. The methods include reducing marine fouling, comprising incorporating an anticoagulant compound into a marine coating. In addition, the methods include identifying compounds useful for reducing marine fouling, comprising measuring either blood coagulation or barnacle cement polymerization in the presence and absence of the compound, wherein a reduction in the blood coagulation or the barnacle cement polymerization in the presence of the compound identifies the compound as useful for reducing marine fouling. The coagulation or the polymerization can be measured by a serine protease activity or a transglutaminase activity.

Abstract: A method for preparing an EDTA-Tris composition which comprises the steps of: mixing ethylenediaminetetraacetic acid (EDTA) USP with tris(hydroxymethyl)aminomethane (Tris) USP to provide an EDTA-Tris USP mixture; and buffering the EDTA-Tris USP mixture with a pH adjuster to a pH of between about 7.9 and 8.10.

Abstract: A process for the preparation of alkylene diamine triacetic acid (derivatives) which comprises the conversion of an alkylene diamine (derivative) to a metal salt of an alkylene diamine triacetic acid (derivative). The reaction is carried out in the presence of a polyvalent metal ion Ma+ and the entire reaction is carried out under hydrolyzing conditions if any of the reactants contain or form nitrile or amide groups.

Abstract: The invention describes a process for the preparation of (S,S)-N,N′-ethylenediaminedisuccinic acid or analogous compounds or their salts by reaction of L-aspartic acid, L-glutamic acid or L-cysteic acid with 1,2-bissulfooxyethane, 1,3,2-dioxathiolane 2,2-dioxide or mixtures thereof or 1,3-bissulfooxy-2-hydroxypropane in the presence of a base, and optional subsequent acidification with an acid. Also described is a process for the preparation of (S,S)-N,N′-ethylenediaminedisuccinic acid or analogous compounds or their salts by reaction of N-(2-sulfooxyethyl)-L-aspartic acid or its salts with L-aspartic acid or corresponding compounds based on L-glutamic acid, L-cysteic acid and/or 1,3-bissulfooxy-2-hydroxypropane in the presence of a base, and optional subsequent acidification with an acid.

Abstract: Described are diester amine adducts of formula (1) wherein R1, R2, R3, R4 are each independently of one another C4-C22alkyl; C2-C22alkenyl; or C5-C7cycloalkyl; X1 and X2 are each independently of the other hydrogen, C1-C4alkyl; C2-C4hydroxyalkyl or C2-C4hydroxyhaloalkyl; Y is a radical of formula (1b); A1 is C2-C3alkylene or 2-hydroxy-n-propylene; X3 is hydrogen; C1-C4alkyl, C2-C4hydroxyalkyl; or C2-C4hydroxyhaloalkyl; (A) is an asymmetrical carbon atom in the R- or S-configuration, wherein, if C1=R, C2=R; C1=S, C2=S; and C1=R; C2=S; m1 is 1 or 2; and n is an integer from 1 to 4; p is 0 or 1; which adducts may be in the form of free bases or ammonium salts. Said compounds are precursors of compounds having good complex-forming properties and are thus able to effectively bind heavy metal ions such as iron, zinc, magnesium or copper ions and to prevent metal-initiated oxidations after enzymatic or chemical cleavage.

Abstract: A method for producing highly purified crystals of tetrasodium. Salt of ethylenediaminetetraacetic acid including reacting ethylene diamine, NaCN and formalin in the presence of an alkali to yield a solution containing EDTA4Na and impurities. This solution is subjected to crystallization over a solvent to form EDTA4Na crystals. The solvent is a mixture of methanol and an alcohol of either ethanol or propanol. The methanol has a ratio by weight to the alcohol of 1:0.43-4.0. The EDTA4Na crystals are then recovered after subjecting the solution to crystallization.

Abstract: Aliphatic primary alcohols, including aliphatic primary alcohols possessing one or more oxygen, nitrogen and/or phosphorus heteroatoms that may be atoms substituting for carbon atoms in the alkyl group or component atoms of substituents on the alkyl group, were converted into salts of carboxylic acids by contacting an alkaline aqueous solution of the primary alcohol with a catalyst comprising cobalt, copper, and at least one of cerium, iron, zinc, and zirconium. Diethanolamine, for example, was converted to sodium iminodiacetate by treatment in an aqueous medium containing sodium hydroxide with a catalyst that was obtained by reducing a mixture of cobalt, copper, and zirconium oxides with hydrogen.

Abstract: The present invention has for its object to provide a method for producing an L-allysine acetal which involves a fewer steps and is efficient. This invention relates to method for producing an L-allysine acetal which comprises; converting a D,L-allysine acetal of the following general formula (1) (wherein R1 and R2 are the same or different, and each of them represents an alkyl group having 1 to 8 carbon atoms, or they combinedly form a ring and represent an alkylene group having 2 to 8 carbon atoms) to a mixture of a 2-oxo-6,6-dialkoxyhexanoic acid of the following general formula (2) (wherein R1 and R2 are as defined above) and an L-allysine acetal of the following general formula (3) (wherein R1 and R2 are as defined above) by reacting in the presence of an enzyme capable of stereoselective oxidative deamination of D-amino acids and; isolating said L-allysine acetal after said converting.

Abstract: Catalyst for dehydrogenating amino alcohols to aminocarboxylic acids or ethylene glycol (derivatives) to oxycarboxylic acids, said catalyst containing zirconium, copper and possibly an additional metal, whereby the cited metals are precipitated as hydroxides, washed, dried, calcined, and reduced, preparable in that zirconium hydroxide is precipitated from an aqueous zirconium salt solution using a base until a pH of 4 to 10 is attained, the aqueous solution of a copper salt and possibly of an additional salt is added to the zirconium hydroxide suspension, and by adding further base copper hydroxide and possibly the hydroxide of the metal contained in the additional salt is precipitated until a pH of 8 to 14 is attained, the suspension obtained is filtered, washed, dried, calcined in air at 450 to 600.degree. C. for 2 to 4 hours and finally reduced at 200 to 250.degree. C. in a hydrogen stream for 2 to 4 hours.

Abstract: The invention relates to a pharmaceutically acceptable prodrug which is a covalent conjugate of a pharmacologically active compound and an intracellular transporting adjuvant, characterized by the presence of a covalent bond which is scission-sensitive to intracellular enzyme activity. The prodrug may be used in a technique for treating a condition or disease in a human related to supranormal intracellular enzyme (.e.g. phospholipase and/or esterase) activity, whereby on administering it to a human having such condition or disease, the bond is broken in response to such activity, and the pharmacologically active compound accumulates selectively within cells having such supranormal intracellular enzyme activity. Exemplary conjugates are esters of the carboxylic function in the formula, with e.g. heptanoyl-sn-3-glycerophosphoryl-choline or octanoyl-sn-3-glycerophosphoryl-choline.

Abstract: A process for the preparation of macromolecular chelants characterized by a high content in chelant groups per macromolecule.

Abstract: Linear oligomer polychelant compounds and chelates formed therewith have alternating chelant and linker moieties bound together by amide or ester moieties. The compounds have between 3 and 100 chelant moieties, at least one of which complexes a paramagnetic metal ion. The polychelants and especially their paramagnetic metal polychelates are particularly suitable for diagnostic imaging.

Abstract: Diethylenetriaminepentaacetic acid monoamide derivatives, their complexes and complex salts, containing an element of atomic numbers 21-29, 31, 32, 39, 42-44, 49 or 57-83, pharmaceutical agents containing these compounds, their use as contrast media and process for their production.

Abstract: A compound of the following formula ##STR1## wherein m is an integer of 1 to 3, R.sub.1 and R.sub.2 are the same or different and each is hydrogen atom or lower alkyl, and R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are the same or different and each is hydroxy or a group of the formula ##STR2## (wherein n is 0 or 1, X is --NH-- or --O--, Y is alkylene, A is hydrogen atom, lower alkyl, lower alkoxy, halogen atom or trifluoromethyl, and B is alkyl or alkenyl), with the proviso that two or three of R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are hydroxyl groups and that when two of them are hydroxyl groups, the cases where R.sub.3 and R.sub.5 are hydroxy, and R.sub.4 and R.sub.6 are hydroxy are excluded; a complex compound comprising said compound and a metallic atom; and a diagnostic agent containing said complex compound. The above compound is useful as a chelating agent and the complex compound comprising said compound and a metallic atom exhibits superior characteristics as a contrast medium for image diagnosis.

Abstract: A compound of the following formula ##STR1## wherein m is an integer of 1 to 3, R.sub.1 and R.sub.2 are the same or different and each is hydrogen atom or lower alkyl, and R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are the same or different and each is hydroxy or a ##STR2## (wherein n is 0 or 1, X is --NH-- or --O--, Y is alkylene, A is hydrogen atom, lower alkyl, lower alkoxy, halogen atom or trifluoromethyl, and B is alkyl or alkenyl), with the proviso that two or three of R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are hydroxyl groups and that when two of them are hydroxyl groups, the cases where R.sub.3 and R.sub.5 are hydroxy, and R.sub.4 and R.sub.6 are hydroxy are excluded; a complex compound comprising said compound and a metallic atom; and a diagnostic agent containing said complex compound. The above compound is useful as a chelating agent and the complex compound comprising said compound and a metallic atom exhibits superior characteristics as a contrast medium for image diagnosis.

Abstract: There are provided chelating agents particularly useful for the preparations of diagnostic and therapeutic agents for magnetic resonance imaging, scintigraphy, ultrasound imaging, radiotherapy and heavy metal detoxification, said agents being compounds of formula X--CHR.sub.1 --NZ--(CHR.sub.1).sub.n --A--(CHR.sub.1).sub.m --NZ--CHR.sub.1 --X wherein (each of the groups Z is a group --CHR.sub.1 X or the groups Z together are a group --(CHR.sub.1).sub.q --A'--(CHR.sub.1).sub.r --, where A' is an oxygen or sulphur atom or a group --N--Y; A is a group --N--Y or A--(CHR.sub.1).sub.m -- represents a carbon-nitrogen bond or, when the groups Z together are a group --(CHR.sub.1).sub.q --A'--(CHR.sub.1).sub.r --, A may also represent an oxygen or sulphur atom; each Y, which may be the same or different, is a group --(CHR.sub.1).sub.p --N(CHR.sub.1 X).sub.2 or a group --CHR.sub.1 X; each X, which may be the same or different, is a carboxyl group or a derivative thereof or a group R.sub.1 ; each R.sub.

Abstract: A process for removing metal salts from an H.sub.4 EDTA precipitate by esterification with an esterification reagent to produce an esterification mixture comprising a solid metal salt an EDTA ester and thereafter separating the solid metal salt from the esterification mixture.

Abstract: Novel magnetic resonance imaging agents comprise complexes of paramagnetic ions with aminoalkylamide derivatives of diethylenetriaminepentaacetic acid ("DTPA") or ethylenediaminetetraacetic acid ("EDTA") or other polyaminocarboxylic or cyclic polyaminocarboxylic chelating agents. These novel imaging agents are characterized by excellent NMR image-contrasting properties and by high solubilities in physiological solutions.A novel method of performing an NMR diagnostic procedure involves administering to a warm-blooded animal an effective amount of a complex as described above and then exposing the warm-blooded animal to an NMR imaging procedure, thereby imaging at least a portion of the body of the warm-blooded animal.

Abstract: A stable, injectable pharmaceutical composition of vinca dimer salts. The compositions are in the form of an aqueous solution comprising per 1 ml of solution:from about 0.2 to about 2 mg of one or more pharmaceutically acceptable vinca dimer salts;from about 0.1 to about 1.0 mg of a pharmaceutically acceptable ethylenediamine-tetraacetic acid (EDTA) salt;acetate buffer in an amount necessary to maintain said aqueous solution at a pH of from about 3.0 to about 5.5; andfrom about 1.5 to about 2.5 mg of a preservative selected from methyl paraben, propyl paraben and mixtures thereof.

Abstract: This invention relates to amino acid, dipeptide and tripeptide derivatives of 2,6-diamino-3-haloheptanedioic acids, processes for preparing the same, and their use as antibacterial agents.

Abstract: Species-linked diamine triacetic acids of the formula ##STR1## wherein T is an organic species containing at least one amine, hydroxyl, or thio functional group, L is the residue of at least one of those functional groups and R is a two or more atom long covalent bridge, are disclosed. Methods for their preparation, for the preparation of metal chelates from them and for the use of the chelates are also disclosed. In a preferred embodiment, the metal ions employed in the formation of the chelates are rare earth metal ions capable of forming fluorescent chelates which can in turn be employed in fluoroassay techniques.

Abstract: The solid oxalate of a catalytic metal such as cobalt, typically formed as an undesired and useless by-product during the liquid-phase oxidation of an organic compound, typically a hydrocarbon, in the presence of a homogeneous catalyst comprising said metal, is treated to convert the metal moiety to a reusable form by a process comprising leaching the metal oxalate with an aqueous solution of a soluble salt of ethylenediaminetetraacetic acid (EDTA). The resulting solution of EDTA-metal complex or chelate is then mixed with a soluble calcium salt to precipitate the oxalate moiety as insoluble calcium oxalate leaving the metal-EDTA complex in solution. After removing the resulting solid calcium oxalate, the remaining filtrate is acidified to convert the metal moiety to a simple salt which can be recycled to the liquid-phase oxidation, while the EDTA is precipitated as a solid which can also be recovered and re-used in the complexation step of the process.

Abstract: Species-linked diamine triacetic acids of the formula ##STR1## wherein T is an organic species containing at least one amine, hydroxyl, or thiol functional group, L is the residue of at least one of those functional groups and R is a two or more atom long covalent bridge, are disclosed. Methods for their preparation, for the preparation of metal chelates from them and for the use of the chelates are also disclosed. In a preferred embodiment, the metal ions employed in the formation of the chelates are rare earth metal ions capable of forming fluorescent chelates which can in turn be employed in fluoroassay techniques.

Abstract: A process for the preparation of dibenzothiazyl disulfide by oxidation of mercaptobenzothiazole in aqueous suspension by means of hydrogen peroxide, in which the oxidation is effected in the presence of ethylenediaminetetraacetic acid or an alkali metal salt derived therefrom.

Abstract: A carboxylic acid is prepared by contacting an aqueous solution of the alkali metal or ammonium carboxylate with a liquid cation exchange agent dissolved in an organic solvent in which the carboxylic acid is substantially water immiscible. As an example, an aqueous solution of trisodium N-(2-hydroxyethyl)ethylenediaminetriacetate is contacted with di(2-ethylhexyl)phosphoric acid in kerosene to thereby form N-(2-hydroxyethyl)ethylenediaminetriacetic acid in the aqueous solution.

Abstract: A method of economically producing a relatively rapidly soluble machine handleable particulate composite material from a material of relatively low solubility comprising pulverizing a material of low solubility, selecting a first appropriate size fraction from the pulverized material and mixing the selected fraction with a predetermined proportion of water to obtain a composite. The composite is dried at a predetermined temperature for a specified time. The dried composite is pulverized and a second selected appropriate size fraction is obtained. The second size fraction possesses increased solution solubility and machine handleability properties over the starting relatively low solubility material.